SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

The study will be conducted in adult patients with Chemotherapy-induced Peripheral Neuropathy (CIPN) that has been persistent for at least 3 months following completion of chemotherapy. A total of 60 patients will be enrolled in equal numbers of a placebo group and two different SON-080 dose groups. Treatment period will be 12 weeks long and patients will be followed-up for an additional 12 weeks.

Acronym:

SON-080

ACTRN/NCT /ethics:

NCT05435742

Scientific title:

SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

Sponsor / Cooperative group:

Sonnet BioTherapeutics